Research Reports

The purpose of this cybersecurity and data privacy regulatory scan is to understand the current and forthcoming regulatory landscape related to cybersecurity and consumer data privacy.

All CHPA manufacturer members (62 in total) were asked to participate in the first survey of diversity, equity, and inclusion in the industry. The survey was conducted from March – July 2022.

This report summarizes findings on issues associated with OTC drugs and dietary supplements in the environment with a focus on emerging issues and chemicals of concern.

The Medicare Advantage health insurance market represents an attractive and rapidly growing opportunity in the Consumer Healthcare and OTC Medicines industry.

Consumer self-care changed during the COVID-19 pandemic. This report from IRI and CHPA divides consumers into seven distinct segments and discussed how CPGs and retailers can reach them with the right health and wellness solutions.

CHPA’s “Insights with Impact” series features Cindy Sanders, Co-Publisher/Managing Editor of Nashville Medical News, who discusses the growing interest in over-the-counter access to oral contraceptives.

List of laws by state summarizing sales restrictions of dextromethorphan to minors.

This update includes any new statutes or laws passed in states regarding CBD labeling laws, as well as including any regulatory standards regarding CBD labeling laws in those states from spring to fall 2020.

State by state listing of restrictions and regulations concerning distribution of OTC product samples.

State by state listing of what entities are permitted to alter controlled substance schedules.